Table 3 Relevance of the highlighted text fragments among relevant sentencesa
Report section | Data element | Relevant sentences, n Totalb | Fragments, n totalc | Relevant fragments, n (%)d | Exact matches, n (%)d | Partial matches, n (%)d |
|---|---|---|---|---|---|---|
Meta information | Funding source | 79 | 157 | 124 (79.0) | 24 (15.3) | 100 (63.7) |
Funding number | 35 | 54 | 44 (81.5) | 27 (50.0) | 17 (31.5) | |
Registration number | 63 | 104 | 104 (100.0) | 103 (99.0) | 1 (1.0) | |
Enrollment | Eligibility criteria | 110 | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Sample size | 125 | 125 | 110 (88.0) | 92 (73.6) | 18 (14.4) | |
Enrollment start date | 55 | 51 | 51 (100.0) | 43 (84.3) | 8 (15.7) | |
Enrollment end date | 56 | 50 | 47 (94.0) | 45 (90.0) | 2 (4.0) | |
Early stopping | 7 | 3 | 3 (100.0) | 1 (33.3) | 2 (66.7) | |
Intervention | Experimental arm(s) | 123 | 133 | 74 (55.6) | 15 (11.3) | 59 (44.4) |
Control arm(s) | 121 | 62 | 55 (88.7) | 34 (54.8) | 21 (33.9) | |
Route of administration | 32 | 34 | 30 (88.2) | 27 (79.4) | 3 (8.8) | |
Dose | 50 | 77 | 70 (90.9) | 26 (33.8) | 44 (57.1) | |
Frequency of administration | 45 | 61 | 55 (90.1) | 44 (72.1) | 11 (18.0) | |
Duration of treatment | 57 | 56 | 48 (85.7) | 35 (62.5) | 13 (23.2) | |
Outcome | Primary outcome(s) | 95 | 78 | 74 (94.9) | 55 (70.5) | 19 (24.4) |
Primary outcome time point | 76 | 86 | 78 (90.7) | 28 (32.6) | 50 (58.1) | |
Secondary outcome(s) | 75 | 53 | 51 (96.2) | 16 (30.2) | 35 (66.0) | |
Secondary outcome time point | 43 | 53 | 51 (96.2) | 20 (37.7) | 31 (58.5) | |
Summary measure | Median (IQR), n | 57 (54) | 59 (33) | 53 (47 to 74) | 27 (15 to 41) | 18 (4 to 34) |
Median (IQR), % | - | - | 90.4 (86.2 to 96.9) | 52.4 (32.8 to 73.2) | 28.0 (14.7 to 57.9) |